Claim · 2020-10-28 · announcement · Stated in source · Supported

insitro announced on 28 October 2020 a collaboration with Bristol Myers Squibb, stating a $50 million upfront payment, eligibility for $20 million in near-term operational milestones and up to an aggregate of more than $2 billion in discovery, development, regulatory and commercial milestones.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

insitro → announced a partnership with → Bristol Myers Squibb

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

insitroannounced a partnership with ↓Bristol Myers Squibb

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2020-10-28 · announcement Records dated 2020 →
Activity stage: announced

Scope and limitsAnnounced terms as insitro states them. The milestone amounts are "up to" and conditional; they are not payments, and the headline "total potential deal value" is not recorded as a value received.

The evidence 01

primary sourceSupports the claim

insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

insitro · 2020-10-28

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“insitro will receive $50 million in an upfront payment and will be eligible to receive an additional $20 million in near term operational milestones and up to an aggregate of more than $2 billion in discovery, development, regulatory and commercial milestones”

Location in source fourth paragraph

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: insitro
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 78f36254fb347db6edde36e893c7297ead44e75c48b4ae219b11bd09aaec178c). insitro news page, dated 10/28/2020 on the page, as served on 2026-10-30. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: insitro, “insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia”, 2020-10-28.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (41 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A9) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An organisation announced a collaboration or partnership with a named counterparty, as the announcement states it (stage announced). It is not evidence that the work was performed, that a payment was made or that the arrangement continues; an “up to” amount stays in the statement.

Date. Date of insitro's release.

Record ID aib-co-insitro-bms-2020